当前位置: 首页 >> 检索结果
341. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial.
作者: Sebastiaan Dhont.;Sara Moura Ferreira.;Xavier Galloo.;Pieter Martens.;Evelyne Meekers.;Katrien Tartaglia.;Sébastien Deferm.;Lieven Herbots.;Wilfried Mullens.;Frederik H Verbrugge.;Jan Verwerft.;Philippe B Bertrand.
来源: Circulation. 2026年153卷25期1973-1983页
Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated.
342. Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
作者: Ahmad Masri.;Francesco Cappelli.;Margot K Davis.;Marianna Fontana.;Pablo Garcia-Pavia.;Julian D Gillmore.;Mazen Hanna.;Laura Obici.;Scott D Solomon.;Brett W Sperry.;Nobuhiro Tahara.;Márcia Waddington-Cruz.;Arnt V Kristen.;Rodney H Falk.;Sanjiv J Shah.;Jose Nativi-Nicolau.;Nicholas J Viney.;Qingqing Yang.;Jersey Chen.;Sotirios Tsimikas.;Mathew S Maurer.
来源: Circ Heart Fail. 2026年19卷6期e014205页
Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand-conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR.
343. Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study.
作者: Fiyyaz Ahmed-Jushuf.;Michael J Foley.;Shayna Chotai.;Christopher A Rajkumar.;Danqi Wang.;Florentina A Simader.;Krzysztof Macierzanka.;Kayla Chiew.;Sannidhya Misra.;Rupert Williams.;Klio Konstantinou.;Jehangir N Din.;Shah R Mohdnazri.;Peter D O'Kane.;Peter Haworth.;Sukhjinder S Nijjer.;Henry Seligman.;Thomas R Keeble.;John R Davies.;Gerald Clesham.;Jonathan Hinton.;James C Spratt.;Jason N Dungu.;Daniel Knight.;Tushar Kotecha.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha K Al-Lamee.
来源: Circulation. 2026年153卷23期1795-1812页
In stable coronary artery disease, the primary goal of percutaneous coronary intervention (PCI) is symptom relief. Fractional flow reserve (FFR) and nonhyperemic pressure ratios such as resting full-cycle ratio (RFR) are used to guide revascularization. Although these indices correlate with myocardial ischemia, they have never been validated against the onset of angina. The physiological thresholds for angina, FFRangina and RFRangina, angina (FFRangina at rest and during exercise remain undefined.
344. Contrast-Derived Index of Microcirculatory Resistance: A Novel Index for Measuring Coronary Microvascular Resistance.
作者: Domenico Galante.;Ciro Pollio Benvenuto.;Andrea Viceré.;Simona Todisco.;Chiara Giuliana.;Vincenzo Viccaro.;Pierpaolo Tarzia.;Lazzaro Paraggio.;Mattia Lunardi.;Cristina Aurigemma.;Enrico Romagnoli.;Rocco A Montone.;Gennaro Capalbo.;Carlo Trani.;Filippo Crea.;Francesco Burzotta.;Antonio Maria Leone.
来源: Circ Cardiovasc Interv. 2026年19卷7期e016489页 345. CD40-TRAF2/3/5 Signaling Promotes Cardiac Repair by Mediating Macrophage Efferocytosis After Myocardial Infarction.
作者: Linlin Zhang.;Yanshan Chen.;Pengpeng Xu.;Tao Zheng.;Jie Sheng.;Zhiyue Wang.;Sheng Wang.;Yu Ding.;Jiaqi Lu.;Xingji Liu.;Canbiao Wang.;Yunming Zhang.;Long Ma.;Jing Pan.;Jun Pu.;Longjiang Zhang.
来源: Circulation. 2026年154卷4期354-374页
After myocardial infarction (MI), macrophage-mediated clearance of dead cells, a process known as efferocytosis, represents a pivotal role in tissue remodeling. Efficient efferocytosis contributes to rescuing neighboring viable cardiomyocytes, drives the phenotypic transition of reparative macrophages, and facilitates the resolution of inflammation. In this study, we explored the roles of CD40 and the signals transduced by its 2 downstream adaptor-protein binding sites (TRAF2/3/5 and TRAF6) in the cardiac macrophage efferocytosis after MI.
346. GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
作者: Ruofei Li.;Yushan Tang.;Yuqin Ding.;Pengyan Hu.;Cheng Lv.;Xiayidan Alimu.;Xiaoyi Wei.;Xiaojian Wang.;Miaoqing Hu.;Yanan Zhang.;Yu Zhang.;Yibo Wang.
来源: Circulation. 2026年154卷2期136-155页
Pulmonary hypertension (PH) is a serious complication of heart failure with preserved ejection fraction (HFpEF), for which no targeted therapies are currently available. Endothelial dysfunction plays a crucial role in PH associated with HFpEF (PH-HFpEF), yet its molecular drivers remain poorly defined.
347. Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).
作者: David E Hamilton.;Jackson L Shriver.;Siddharth M Patel.;Jeong-Gun Park.;Zoe E Michos.;Michael R Mathis.;Sarah K Adie.;Carlos L Alviar.;Christopher F Barnett.;David D Berg.;Courtney E Bennett.;Erin A Bohula.;Anthony P Carnicelli.;Lori B Daniels.;Mark W Dodson.;Ann Gage.;Umesh Gidwani.;Michael Goldfarb.;Jason N Katz.;Scott W Ketcham.;Younghoon Kwon.;Evan S Leibner.;Daniel B Loriaux.;Adriana Luk.;Paul Marano.;P Elliott Miller.;Srini V Mukundan.;Alexander I Papolos.;Barbara A Pisani.;Alastair G Proudfoot.;Robert O Roswell.;Kevin S Shah.;Michael A Solomon.;Matthew I Tomey.;Sean van Diepen.;Sammy Zakaria.;David A Morrow.;Andrea D Thompson.; .
来源: Circ Heart Fail. 2026年e013778页
The paucity of data to guide selection of specific vasoactive agents in patients with cardiogenic shock (CS) may lead to variability in practice patterns. The level of variability and specific factors that are associated with the use of vasoactive medications and inodilators have not been previously described.
348. Opportunistic CT Fatty Muscle Fraction for Outcome Prediction in Patients Undergoing Transcatheter Mitral Valve Edge-to-Edge Repair.
作者: Babak Salam.;Marcel Weber.;Alois M Sprinkart.;Sebastian Nowak.;Maike Theis.;Muntadher Al-Zaidi.;Atsushi Sugiura.;Tetsu Tanaka.;Tatjana Dell.;Alexander Isaak.;Daniel Kuetting.;Sebastian Zimmer.;Georg Nickenig.;Julian A Luetkens.;Johanna Vogelhuber.
来源: Circ Cardiovasc Imaging. 2026年e018763页
Frailty is a risk factor for adverse outcomes in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) and is interrelated with sarcopenia. This study aimed to investigate the prognostic value of fatty muscle fraction (FMF), measured from routine preinterventional computed tomography, as an imaging biomarker for frailty in patients undergoing M-TEER.
349. Advanced Imaging in Loeffler Endocarditis in the Setting of Dupilumab-Associated Hypereosinophilia: Diagnostic Utility of Cardiac MRI.
作者: Felipe I Contreras-Yametti.;Annalisa Filtz.;Sanjana Nagraj.;Daniel Lorenzatti.;Kirtipal Bhatia.;Franco J Cossettini.;Aldo L Schenone.;Leandro Slipczuk.;Mario J Garcia.
来源: Circ Cardiovasc Imaging. 2026年19卷6期e019739页 350. Implications of Cranial Arterial Stenosis and Dolichoectasia for Cerebral Small-Vessel Disease Etiopathogenesis: Findings From a Prospective Mild Stroke Cohort.
作者: Fei Han.;Una Clancy.;Carmen Arteaga-Reyes.;Michael J Thrippleton.;Maria Del C Valdés Hernández.;Daniela Jaime Garcia.;Michael S Stringer.;Ellen Backhouse.;Francesca M Chappell.;Yajun Cheng.;Dillys Xiaodi Liu.;Junfang Zhang.;Angela C C Jochems.;Eleni Sakka.;Charlotte Jardine.;Gayle Barclay.;Donna McIntyre.;Iona Hamilton.;Rosalind Brown.;Yi-Cheng Zhu.;Fergus N Doubal.;Joanna M Wardlaw.
来源: Circulation. 2026年153卷23期1813-1826页
Stenosis and dolichoectasia of cranial arteries likely reflect distinct mechanisms. Their contributions to lacunar stroke and cerebral small-vessel disease (cSVD) remain contentious. We investigated the associations of large-artery stenosis (LAS) and arterial widening with stroke subtype, cSVD markers, incident infarcts, and clinical outcomes.
351. Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction.
作者: Massimiliano Ansaldo.;Chahida Chaami.;Simone Porcelli.;Roberto Bottinelli.;Chengxin Zhang.;Christopher T A Lewis.;T Scott Bowen.;Robert A E Seaborne.;Hans Erik Bøtker.;Kristian Vissing.;Julien Ochala.
来源: Circ Heart Fail. 2026年19卷6期e013827页
Heart failure with reduced ejection fraction (HFrEF) affects millions worldwide and is characterized by chronic cardiac dysfunction, impaired perfusion, altered skeletal muscle energetics, and, thus, exercise intolerance. Efficient therapeutic strategies reducing the burden of the impaired muscle metabolism in HFrEF are currently lacking. Hence, in the present study, we sought to determine whether myosin dynamics and its important role in ATP consumption can constitute a potent biochemical target to optimize skeletal muscle energy usage in HFrEF.
352. Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease.
作者: Ashish H Shah.;Alexander R Opotowsky.;Jack Rychik.;Richard A Krasuski.
来源: Circ Heart Fail. 2026年19卷6期e014293页 353. Tolerogenic Dendritic Cells Are Pivotal for Pediatric Transplant Operational Tolerance by Restraining Alloreactive T Cells via TGFβRII.
作者: Wai Yen Yim.;Yating Li.;Jincheng Hou.;Yuqi Chen.;Bingchuan Geng.;Matiullah Masroor.;Zongtao Liu.;Yixuan Wang.;Nianguo Dong.
来源: Circ Heart Fail. 2026年19卷6期e014053页 354. One-Year Outcomes of Screen Failures for Transcatheter Tricuspid Valve Repair: Insights From the TriSelect Study.
作者: Felix Rudolph.;Arseniy Goncharov.;Akhil Narang.;Maria L Körber.;Jyothy J Puthumana.;S Christopher Malaisrie.;Zhiying Meng.;Abigail Baldrigde.;Tanja K Rudolph.;Kai P Friedrichs.;Roman Pfister.;James D Thomas.;Max Potratz.;Volker Rudolph.;Charles J Davidson.;Muhammed Gerçek.
来源: Circ Cardiovasc Interv. 2026年e016124页
Observational registries have shown improved survival among patients with severe or greater tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve repair (TTVr) compared with conservative management. However, it remains unclear whether this survival benefit persists when specifically comparing patients undergoing TTVr with those who screen failed.
355. Postapproval Study Outcomes of Muscular Ventricular Septal Defect Closure With the Amplatzer Muscular VSD Occluder.
作者: Athar M Qureshi.;Henri Justino.;Carl Owada.;Mohammed Numan.;Makram Ebeid.;Thomas J Forbes.;David Nykanen.;Daisuke Kobayashi.;Jillian Kolles.;Dan Gutfinger.;David Balzer.
来源: Circ Cardiovasc Interv. 2026年19卷6期e016121页
The Amplatzer Muscular Ventricular Septal Defect (VSD) Occluder (Abbott Structural Heart, Plymouth, MN) was approved by the US Food and Drug Administration in 2007. As a condition of approval, a postapproval study was required to further evaluate its safety and effectiveness. This study reports the clinical outcomes from the postapproval study over 5 years of follow-up.
356. Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study.
作者: David E Kandzari.;Andrea Mignatti.;Annapoorna Kini.;Garrett Wong.;Gagan Singh.;Azeem Latib.;Ricardo Costa.;Carlos M Campos.;Alexandre Abizaid.
来源: Circ Cardiovasc Interv. 2026年e016010页
An early feasibility study was conducted to evaluate the performance of a low-profile, microaxial percutaneous ventricular assist device (pVAD; Supira Medical, Los Gatos, CA) capable of up to 5.5 L/min flow to provide hemodynamic support in high-risk percutaneous coronary intervention.
357. Daily Stellate Ganglion Phototherapy for Ventricular Arrhythmias: A Noninvasive Neuromodulation Approach for Outpatient Care.
作者: Yoshihiro Harano.;Yasutoshi Shinoda.;Yuto Iioka.;Yuka Oda.;Yuichi Hanaki.;Hiro Yamasaki.;Miyako Igarashi.;Tomoko Ishizu.;Akihiko Nogami.;Yuki Komatsu.
来源: Circulation. 2026年153卷18期1439-1441页 |